{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-23-000018","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.193026+00:00","generated_at":"2026-06-18T07:11:50.886840+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Black Diamond Therapeutics reports Q4 net loss $21.1M; cash $122.8M; BDTX-1535 update H2 2023","bullets":["Net loss $21.1M in Q4 2022, full year net loss $91.2M (vs $125.6M in 2021).","Cash, cash equivalents and investments $122.8M as of Dec 31, 2022; sufficient into Q3 2024.","Phase 1 update for EGFR inhibitor BDTX-1535 expected H2 2023; trial actively recruiting.","FDA cleared IND for BRAF/RAS inhibitor BDTX-4933; Phase 1 start expected H1 2023.","Spinout of Launchpad Therapeutics with $30M Series A led by Versant and NEA; BDTX retains minority stake."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-23-000018","json":"https://secwatch.observer/filing/0001701541-23-000018.json","markdown":"https://secwatch.observer/filing/0001701541-23-000018.md","text":"https://secwatch.observer/filing/0001701541-23-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154123000018/0001701541-23-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154123000018/bdtx-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:11:50.886840+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56c7e0f17bfe5714e5467800dc5f4cccdbf9de29","claim":"Black Diamond Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 9, 2023, Black Diamond Therapeutics, Inc. announced its financial results for the year and three months ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000170154123000018/0001701541-23-000018-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}